It will investigate a novel treatment approach for diabetic macular edema (DME), which causes vision impairment in diabetic patients. It will focuse on the efficacy and safety of administering triamcinolone acetonide via suprachoroidal injection, targeting the space between the sclera and choroid.

This method aims to enhance drug delivery to the retina, potentially improving outcomes compared to conventional treatments. Participants receive suprachoroidal injections, and the study measures changes in macular thickness and visual acuity. The study's findings could offer a promising alternative to existing DME treatments, aiming to provide better management of the condition and improved patient quality of life.

Inclusion Criteria:

• Above 30 years old patients male and female
• Diabetic patient
• Diabetic patient for more than 2 years
• Macular thickness of more than 280um

Exclusion Criteria:

• Patient below 30 years
• Patients having media opacity
• Patients with other systemic problems
• Uncooperative patients

Diabetic Macular Edema patient having Diabetes for more than 2 years